David Altshuler sold $611k of VRTX
EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA. 1,272 shares at an average of $480.00, traded Feb 27, 2025, filed Feb 28, 2025.
Score components
- +15RoleOfficer
- +20Trade size$611k at market
- 0Share of holdings soldSold 3.7% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-25-000120, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2025 | FTax withholding Common Stock10b5-1 | -5,954 | $479.61 | $2.9M | 34,246 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock10b5-1 | -1,272 | $480.00 | $611k | 32,974 | Feb 28, 2025 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $156k 347 shares | -2% | |
| 25Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $1.1M 2,500 shares | -13% | |
| 9Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $281k 694 shares | -4% | |
| 5Weak | VERTEX PHARMACEUTICALS INC / MA | Sangeeta N. Bhatia director | $103k 266 shares | -6% | |
| 75Notable | VERTEX PHARMACEUTICALS INC / MA | Reshma Kewalramani CEO & President | $3.9M 10,000 shares | +9% | |
| 65Notable | VERTEX PHARMACEUTICALS INC / MA | Bruce I Sachs director | $1.9M 5,000 shares | +13% | |
| 3Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $22k 52 shares | -0% | |
| 15Weak | VERTEX PHARMACEUTICALS INC / MA | Sangeeta N. Bhatia director | $202k 400 shares | -8% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $1.6M 3,231 shares | -12% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $1.6M 3,231 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.